

# Designed For Conformability

## Building Confidence in the Treatment of Type B Dissection




### Worldwide data supports performance in the treatment of all Type B dissections


- ▶ Gore GREAT Registry<sup>1</sup> provides worldwide experience and outcomes in real-world dissection use.
- ▶ Conformable GORE® TAG® Device clinical experience continues to demonstrate safety and efficacy in the treatment of Type B dissection.

### GREAT Dissection Experience

#### Dissection Sub-Types Treated



#### Proximal Landing Zone<sup>2</sup>



Images courtesy of Nimesh Desai, MD

#### Adverse Event

Adverse Event	Gore Acute Complicated Type B Dissection Clinical Study (08-01) <sup>3</sup>	GREAT Data <sup>4</sup>
Dissection-Related Survival	90 %	96.4 %
Procedural Survival	100 %	100 %
RTAD	4 %	0.6 %
Stroke	4 %	1.2 %
Type IA Endoleak	2.6 %	0 %
Device Compressions	0 %	0 %
Paraparesis / Paralysis	2.6 %	1.2 %
Conversion	0 %	0.6 %

1. The GREAT Registry is a prospective, observational, multicenter registry to actively track Gore commercial aortic endovascular device performance and associated patient outcomes in global markets with 10 years of follow-up.
2. The GORE® TAG® Thoracic Endoprosthesis is not indicated for the treatment of Zone 0 and Zone 1.
3. Device-related retrograde Type A dissection (RTAD), debilitating stroke, endoleak and paraparesis / paralysis persisting at 12 months post-procedure, device compressions and conversions occurring within 12 months post-procedure.
4. Includes all Type B dissections, events occurring within 12 months post-procedure.

**INDICATIONS FOR USE IN THE US:** The GORE® TAG® Thoracic Endoprosthesis is intended for endovascular repair of all lesions of the descending thoracic aorta, including: Isolated lesions in patients who have appropriate anatomy, including: adequate iliac / femoral access, aortic inner diameter in the range of 16–42 mm, ≥ 20 mm non-aneurysmal aorta proximal and distal to the lesion; Type B dissections in patients who have appropriate anatomy, including: adequate iliac / femoral access, ≥ 20 mm landing zone proximal to the primary entry tear; proximal extent of the landing zone must not be dissected, diameter at proximal extent of proximal landing zone in the range of 16–42 mm. **CONTRAINDICATIONS:** Patients with known sensitivities or allergies to the device materials; patients who have a condition that threatens to infect the graft. Refer to *Instructions for Use* at [goremmedical.com](http://goremmedical.com) for a complete description of all warnings, precautions, and adverse events. **INDICATIONS FOR USE UNDER CE MARK:** The GORE® TAG® Thoracic Endoprosthesis is indicated for endovascular repair of the descending thoracic aorta. **CONTRAINDICATIONS:** Patients with known sensitivities or allergies to the device materials; patients with a systemic infection who may be at increased risk of endovascular graft infection. Refer to *Instructions for Use* at [goremmedical.com](http://goremmedical.com) for a complete description of all warnings, precautions, and adverse events. Rx only



Products listed may not be available in all markets.

GORE®, PERFORMANCE THROUGH EXPERIENCE, TAG®, and designs are trademarks of W. L. Gore & Associates.  
© 2016 W. L. Gore & Associates, Inc. AV0053-EN2 AUGUST 2016

To view further dissection information, visit  
[goremmedical.com/aortic/tevar](http://goremmedical.com/aortic/tevar)

PERFORMANCE  
through experience